Table I.

Treatment with anti-TGF-β and anti-IL-4 mAbs weakens therapeutic potential of Salmonella-CFA/1 induced CD4+ T cellsa

TreatmentbCIA/TotalcDay OnsetdMaximum ScoreeAverage ScorefCumulative Scoreg
PBS10/1027.8 ± 1.6107.2 ± 0.7850.4 ± 7.11
H696CD4+ T cells and IgG4/1033 ± 5.3541.44 ± 0.65 *7.78 ± 4.65*
H696CD4+ T cells and anti-IL-48/826.71 ± 2.2983.62 ± 0.9634.87 ± 11.09
H696CD4+ T cells and anti-TGF-β8/827.25 ± 2.43125.75 ± 0.8649.37 ± 10.13
  • a Arthritis was induced in DBA/1 mice with 100 μg bovine CII in CFA on day 0.

  • b Salmonella-CFA/1 primed CD4+ T cells were adoptively transferred to mice with induced arthritis on day 15. i.p. mAb treatments were initiated on day of transfer, then weekly for a total of four doses (1 mg total of mAb/mouse).

  • c Number of mice with CIA/total in a group for 43 days after CII challenge.

  • d Mean day ± SEM of first symptoms onset in diseased mice only.

  • e Maximum score in group in entire observation period.

  • f Average clinical score per group on day 43 postinduction (end of observation period) calculated as sum of individual scores divided by the number of mice in group ± SEM. ∗, p < 0.005 as compared with PBS group; † p < 0.05 as compared with anti-IL-4 or anti-TGF-β mAb-treated group.

  • g Cumulative scores calculated as all scores during the period of observation divided by number of mice in each group. ∗p < 0.005 as compared with PBS- and anti-TGF-β-treated groups; † p < 0.05 as compared with anti-IL-4-treated group.